Corcept Therapeutics INC Form 4 insider transactions

Corcept Therapeutics' Chief Business Officer, Gary Charles Robb, exercised 145,000 stock options and subsequently sold 80,284 shares to cover the exercise price and tax obligations.

Corcept Therapeutics CEO Joseph K. Belanoff exercised 550,000 stock options and transferred the resulting net shares to a revocable living trust.

Corcept Therapeutics director James N. Wilson reported significant changes in his indirect beneficial ownership of company common stock through estate planning transactions.

Corcept Therapeutics' Chief Development Officer, William Guyer, exercised stock options and subsequently sold a significant portion of the acquired shares under a pre-arranged 10b5-1 plan.

Corcept Therapeutics' Chief Business Officer, Gary Charles Robb, reported recent acquisitions of common stock through a purchase plan and restricted stock awards, alongside a disposition for tax withholding.

Corcept Therapeutics' Chief Development Officer, William Guyer, filed an amended Form 4 to correct details regarding past stock transactions and ownership.

Corcept Therapeutics' President of Endocrinology, Sean Maduck, reported exercising stock options, selling shares under a 10b5-1 plan, and acquiring new shares through a company purchase plan.

Joseph Douglas Lyon, Corcept Therapeutics' Chief Accounting & Technology Officer, exercised stock options, sold shares under a 10b5-1 plan, and acquired new shares and restricted stock awards.

Corcept Therapeutics CFO Atabak Mokari reported acquiring company shares through a purchase plan and managing tax obligations related to restricted stock unit vesting.

Corcept Therapeutics CEO Joseph K. Belanoff sold 40,000 shares of common stock for approximately $3.19 million as part of a pre-arranged trading plan.

Corcept Therapeutics' Chief Development Officer, William Guyer, sold 4,500 shares of common stock for approximately $80.90 per share as part of a pre-scheduled trading plan.

Corcept Therapeutics' Chief Development Officer, William Guyer, exercised stock options for 20,000 shares and subsequently sold all of them for approximately $1.5 million.

Corcept Therapeutics' Chief Accounting & Technology Officer, Joseph Douglas Lyon, exercised stock options and subsequently sold 5,000 shares of common stock under a pre-arranged 10b5-1 plan.

Corcept Therapeutics CEO Joseph K. Belanoff sold 40,000 shares of common stock for approximately $2.98 million in pre-scheduled transactions.

Sean Maduck, President of Corcept Endocrinology, exercised stock options and subsequently sold 20,000 shares of Corcept Therapeutics common stock.

Corcept Therapeutics director Daniel N. Swisher Jr. exercised stock options and immediately sold 2,200 shares of common stock for $87.54 per share.

Corcept Therapeutics Chief Development Officer William Guyer exercised stock options and subsequently sold 20,000 shares of common stock.

Corcept Therapeutics CEO Joseph K. Belanoff sold 40,000 shares of common stock in early October 2025 through a pre-arranged Rule 10b5-1 trading plan.

Corcept Therapeutics' Chief Accounting & Technology Officer, Joseph Douglas Lyon, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 plan.

Corcept Therapeutics officer Sean Maduck exercised stock options and subsequently sold a significant number of common shares on October 1, 2025, under a pre-arranged 10b5-1 plan.

Corcept Therapeutics' Chief Development Officer, William Guyer, reported gifting 200 shares of common stock to a charitable account.

Corcept Therapeutics Director Gillian Cannon donated 7,393 shares of common stock, resulting in zero direct beneficial ownership.

Corcept Therapeutics Director Daniel N. Swisher Jr. exercised stock options and immediately sold the acquired shares under a pre-arranged 10b5-1 plan.

Corcept Therapeutics Director Gillian Cannon exercised 11,000 stock options, resulting in a net acquisition of 7,393 common shares.

Corcept Therapeutics' Chief Development Officer, William Guyer, exercised stock options and subsequently sold a portion of his common stock holdings as part of a pre-arranged trading plan.

Corcept Therapeutics Chief Accounting & Technology Officer Joseph Douglas Lyon reported multiple transactions involving company common stock, including option exercises, sales under a 10b5-1 plan, and acquisition of restricted stock awards.

A Corcept Therapeutics officer exercised stock options and subsequently sold a matching number of shares, while also acquiring new shares and restricted stock awards.

Corcept Therapeutics CEO Joseph K. Belanoff sold 40,000 shares of common stock on September 2, 2025, through a pre-arranged 10b5-1 trading plan.

Corcept Therapeutics' Chief Financial Officer, Atabak Mokari, reported recent stock acquisitions and tax-related dispositions of company common stock.

Corcept Therapeutics' Chief Business Officer, Gary Charles Robb, filed a Form 4 detailing future acquisitions of common stock and a disposition for tax obligations under a 10b5-1 plan.